Cullinan Therapeutics (NASDAQ:CGEM) Posts Earnings Results, Beats Expectations By $0.03 EPS

Cullinan Therapeutics (NASDAQ:CGEM) issued its quarterly earnings results on Tuesday. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.03, FiscalAI reports.

Here are the key takeaways from Cullinan Therapeutics’ conference call:

• CLN-978 (CD19xCD3) is positioned as a potential best-in-class subcutaneous T‑cell engager for autoimmune diseases with company‑sponsored data readouts scheduled in Q2 (SLE, RA), Q3 (multi‑dose RA) and Q4 (Sjögren’s) 2026.
• CLN-049 (FLT3xCD3) showed compelling monotherapy efficacy at ASH, earned FDA Fast Track designation, and the company plans to pick a recommended phase II dose this year and start a pivotal r/r study while initiating a frontline venetoclax combination by year‑end.
• The company completed an NDA submission for zipalertinib, and partner Taiho has finished frontline enrollment with top‑line data expected by year‑end, representing near‑term regulatory/commercial catalysts.
• Cullinan reported >$430 million in cash at year‑end, which management says provides runway into 2029 to fund advancement of CLN‑978, CLN‑049 and other programs.
• Key risks remain: early efficacy datasets are small (e.g., three NHL patients in FIH CLN‑978 work), CRS/ICANS risk requires step‑up dosing and inpatient monitoring initially, and durability/optimal dosing are still unresolved and could affect timelines or labeling.

Cullinan Therapeutics Stock Down 2.6%

Shares of NASDAQ:CGEM opened at $14.91 on Wednesday. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $16.74. The company’s 50 day moving average price is $12.48 and its two-hundred day moving average price is $9.82. The firm has a market cap of $880.88 million, a PE ratio of -4.50 and a beta of -0.15.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Morgan Stanley reiterated an “overweight” rating and set a $30.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, January 8th. Zacks Research cut Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Wedbush boosted their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Finally, Guggenheim started coverage on Cullinan Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $30.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cullinan Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Insiders Place Their Bets

In related news, CEO Nadim Ahmed sold 13,515 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $14.47, for a total transaction of $195,562.05. Following the sale, the chief executive officer owned 390,803 shares of the company’s stock, valued at $5,654,919.41. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jacquelyn L. Sumer sold 3,601 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $14.47, for a total value of $52,106.47. Following the transaction, the insider owned 128,089 shares in the company, valued at approximately $1,853,447.83. This trade represents a 2.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 107,912 shares of company stock valued at $1,420,241 in the last quarter. Company insiders own 6.07% of the company’s stock.

Institutional Trading of Cullinan Therapeutics

Several large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd raised its stake in Cullinan Therapeutics by 62.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after purchasing an additional 1,036 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after buying an additional 2,523 shares in the last quarter. Quarry LP acquired a new stake in Cullinan Therapeutics during the fourth quarter worth about $99,000. Massar Capital Management LP bought a new position in Cullinan Therapeutics in the 2nd quarter valued at about $101,000. Finally, Great Lakes Advisors LLC bought a new position in Cullinan Therapeutics in the 4th quarter valued at about $128,000. 86.31% of the stock is owned by institutional investors and hedge funds.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.